Devinsky O, Vazquez B, Luciano D
Department of Neurology, New York University School of Medicine, Hospital for Joint Diseases, NY 10003.
J Child Neurol. 1994 Oct;9 Suppl 1:S33-45. doi: 10.1177/0883073894009001071.
After a 15-year hiatus, several new antiepileptic drugs have been approved or are under Food and Drug Administration investigation for use in the United States. This article reviews four of these new drugs--felbamate, gabapentin, lamotrigine, and vigabatrin. Although these drugs have been primarily developed for use in adults with partial seizures, they will also likely be used in children with partial epilepsy. Pediatric experience with several of these drugs has demonstrated safety and efficacy in other seizure types and epilepsy syndromes. These drugs will be an important addition to the therapeutic armamentarium for pediatric epilepsy. Additional studies are needed to fully explore the safety and efficacy of these drugs in a variety of pediatric epilepsies and to compare them to existing antiepileptic drugs.
在中断了15年之后，几种新型抗癫痫药物已获批准，或正在接受美国食品药品监督管理局的调查以在美国投入使用。本文回顾了其中四种新药——非氨酯、加巴喷丁、拉莫三嗪和氨己烯酸。尽管这些药物主要是为成人部分性癫痫发作而研发的，但它们也可能用于儿童部分性癫痫。对其中几种药物的儿科应用经验已证明其在其他癫痫类型和癫痫综合征中的安全性和有效性。这些药物将成为儿科癫痫治疗手段的重要补充。还需要进行更多研究，以全面探究这些药物在各种儿科癫痫中的安全性和有效性，并将它们与现有的抗癫痫药物进行比较。
